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INTRODUCTION 
 
 Hypertension is long term medical condition in which the blood pressure is 
persistently elevated in the arteries. 
 
 High arterial blood pressure is one of the most important public health 
problems in both developing and developed countries.  Estimated prevalence of 
hypertension in India   is 29.8% as on 30th April 2014. are usually life style and 
genetic factors(1). Other factors that are associated with developing hypertension 
are excess salt intake, sedentary life style, obesity, smoking and excessive alcohol 
intake. 
 
 High blood pressure is usually presents as asymptomatic. Even though it is 
easily detectable, easily treatable it often leads to severe complication if not 
diagnosed and treated early. 
 
  Long term high blood pressure if untreated is a major risk factor for 
developing cardiac complication such as left ventricular hypertrophy, left 
ventricular dysfunction, congestive cardiac failure, ventricular arrhythmias, 
myocardial infarction and sudden death(2).  
 
Other complications due to hypertension include stroke, hypertensive 
retinopathy, hypertensive nephropathy, aortic dissection etc. Cardiac 
complications are one of the major causes of morbidity and mortality in 
hypertension. Preventing these complications is the major goal of treatment (3). 
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 In India death due to cardio vascular disease is 272 per 100,000 
populations which is relatively high compared to the world average of 235 per 
100,000 populations. Hypertension is directly responsible for 57% of all stroke 
deaths and 24% of all coronary artery disease death in India. 
 
According to new ACC and American Heart Association AHA guide lines 
November 13, 2017.  
 Normal : Blood pressure is less than 120/80 mmHg 
 Elevated blood pressure is systolic between 120 – 129 and diastolic less 
than 80 
 Stage 1 : Hypertension is systolic between 130 – 139 or diastolic between 
80 – 89  
 Stage 2 : Hypertension is systolic at more than 140 or diastolic more than 
90 mmHg  
 
 Hypertension further classified as primary hypertension and secondary 
hypertension. Of these 90 to 95% hypertensive are primary hypertension and are 
due to non-specific factors such as life style factors and genetic factors (4). Life 
style factors that increase the risk of developing hypertension are excessive salt 
intake in the diet, excess body weight, smoking and alcohol use. 
 
Remaining 5 to 10% of cases are classified as secondary hypertension 
which is due to other systemic diseases such as chronic kidney diseases, 
narrowing of the kidney arteries, an endocrine disorder or due to use of birth 
control pills(5).  
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Life style changes and medication will reduce blood pressure and reduce 
the risk of complications due to high blood pressure. Life style modifications are 
weight loss, decreased salt intake, physical exercise and a healthy diet. If life style 
modifications do not reduces high blood pressure then medication should be 
added to reduce high blood pressure.  
 
Several classes of medications collectively known as antihypertensive   
drugs are available for treating high blood pressure. 
 
First line medication for treating hypertension are thiazide – diuretics, 
calcium channel blockers, angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers. These medications either used as a single drug 
therapy or as a combination therapy based on efficacy and tolerability (6). 
 
Resveratrol is a naturally occurring flavonoid phytoalexin having 
antioxidant properties. It is increasingly used in the treatment of various diseases 
due to its cardio protective, ant diabetic and neuroprotective effects. In addition to 
this some studies have shown resveratrol to have vasoprotective properties(7).  
 
EFSA as categorized resveratrol as a food supplement and it can be taken 
without a doctor prescription or recommendation.  Resveratrol appears to control 
high blood pressure when added to a standard antihypertensive treatment by 
increasing the Nitric oxide production, which is an endogenous potent 
vasodilator(8). 
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Several animal studies and clinical trials suggest that resveratrol reduces 
blood pressure significantly when given as add on therapy to antihypertensive 
drugs(9). Hence the open label prospective, randomized, parallel group study is 
undertaken to find out the efficacy and tolerability of resveratrol as an add on 
therapy to standard antihypertensive regimen in reducing blood pressure. 
 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
Hypertension is a chronic condition and plays a major role in causation of 
coronary heart diseases, stroke and other vascular complications. Hypertension 
commonly referred to as “high blood pressure” is a medical condition in which 
the blood pressure is chronically elevated. Hypertension is a major public health 
challenge to population in socio – economic and epidemiological transition. 
 
A practical definition of hypertension is the level of BP at which the 
benefit of treatment outweighs the cost and hazard. 
 
DEFINITION OF HYPERTENSION 
CATEGORY SYSTOLIC  BP DIASTOLIC BP 
BP OPTIMOL < 120 < 80 
NORMAL < 130 85 
HIGH NORMAL 130 – 139 85 - 89 
 
GRADES OF HYPERTENSION  
GRADE 1 ( mild ) 140- 159 90- 99 
GRADE 2 ( moderate ) 160 – 179 100 – 109 
GRADE 3 ( severe ) >180 >110 
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ISOLATED SYSTOLIC HYPERTENSION  
GRADE 1 140 -159 < 90 
GRADE 2 >160 < 90 
 
AETIOLOGY: 
 In 95% of hypertensive patient no specific underlying cause can be found 
and they are called as essential hypertension.  
 
There are many factors that may contribute to the development of essential 
hypertension e.g.: Renal dysfunction, endothelial dysfunction, peripheral 
resistance vessel tone, autonomic tone insulin resistance and neurohumoral 
factors(9). Environmental factors that cause essential hypertension are high salt 
intake, obesity, lack of exercise, heavy consumption of alcohol and impaired 
intrauterine growth. Stress is also known to cause hypertension.  
 
In another 5% of cases hypertension is may be due to a specific disease or 
abnormality leading to sodium retention and / or peripheral vasoconstriction. This 
is called as secondary hypertension(11). 
 
The major risk factor for development of strokes, heart attacks, heart 
failure, arterial aneurysm and chronic renal failure is persistent hypertension. 
Even moderate persistent elevation of arterial blood pressure leads to shortened 
life expectancy. At severely high blood pressure, a person cannot be expected to 
live not more than a few years unless appropriately treated (13). 
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SALT SENSITIVITY: 
 Among the environmental factors that cause hypertension, sodium is the 
most important. There is increasing evidence to suggest that a high salt intake  
(i.e. 7.8g per day) increases blood pressure proportionately. Approximately 60% 
of the essential hypertensive populations are due to high sodium intake (14). In fact 
increasing the amount of salt in a person’s bloodstream causes the body to draw 
more water, thereby increasing the pressure on the blood vessel walls. 
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ROLE OF RENINS: 
 Renin is a hormone secreted by the juxtaglomerular cells of the kidney and 
linked with aldosterone in a negative feedback loop. The level of renin activity is 
very high in hypertensive subjects compared to normotensive individuals(15). But 
some hypertensive patients have low level of renin and it is known as low renin 
hypertension. It is commonly seeing in African American and Japanese. These 
people will respond to diuretic therapy than drugs that interfere with renin – 
angiotensin system.  
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High renin levels predispose to hypertension. 
 Increased renin     increased angiotensin II 
 
Increased vasoconstriction, thirst /ADH and aldosterone 
 
Increased sodium reabsorption in the kidney 
 
Increased blood pressure 
 
GENETICS: 
 Hypertension is one of the most common complex disorders, with genetic 
heritability averaging 30%. Data supporting this view emerge from animal studies 
as well as in population studies in humans(18). 
 
 Most of these studies support the concept that the inheritance is probably 
multifactorial or that a number of different genetic defect each have an elevated 
blood pressure as one of their phenotype expression. More than 50 genes have 
been examined in association studies with hypertension, and the number is 
constantly growing.  
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ETIOLOGY OF SECONDARY HYPERTENSION: 
 Approximately 5% of patients in the world have secondary to identifiable 
specific cause. Secondary hypertension should be always suspected in patients in 
whom hypertension develops after the age of 50 years or at an early age, and in 
those previously well controlled blood pressure but later become refractory to 
treatment(22).  
 
Hypertension resistance to three antihypertensive medications is another 
clue, although diabetes patients need multiple medications. Secondary causes for 
hypertension include genetic syndromes, kidney disease, renal vascular disease, 
primary hyperaldosteronisim, Cushing syndromes, pheochromocytoma,  
coarctation of the aorta and hypertension associated with pregnancy, estogen use, 
hypercalceamia and other medication(24). 
 
Genetics causes  
 Hypertesion is due to mutation in single genes, inherited on a mendelian 
basis. Although it is rare, these conditions provide more insight into blood 
pressure regulation and possible genetic basis of essentials hypertension(18). 
 
 Autosomal dominant cause for early onset hypertension with normal or 
high aldosterone and low renin levels is caused by the formation of a chimeric 
gene encoding both the enzymes responsible for the synthesis of aldosterone and 
for synthesis of cortical(27). As a consequence, aldosterone synthesis which is   
driven by ACTH can be suppressed by exogenous cortisol. In the syndrome of 
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apparent mineralocorticoid excess, early onset hypertension with hypokalemic 
metabolic alkalosis is inherited on an autosomal recessive basis(31). Even thought 
plasma renin is low and plasma aldosterone level is very low, aldosterone 
antagonists are effective in controlling hypertension in these patients. In these 
patients loss of the enzyme 11 beta – hydroxysteroid dehydrogenase, which 
normally metabolizes cortisol and protects the mineralocorticoid receptor in the 
distal nephron due to inappropriate glucocorticoid activation is lost. Similarly 
licorice causes increased blood pressure through inhibition of 11 beta -  
hyroxysteroid dehydrogenase (32).  
 
The syndrome of hypertension seen in pregnancy is inherited as an 
autosomal dominant trait. In pregnancy induced hypertension mutation in the 
mineralocorticoid receptor makes them abnormally responsive to progesterone 
and paradoxically to spironolactone.  
 
Liddles syndrome is an autosomal dominant condition in which early onset 
hypertension is associated with hypokalemia, low renin, and low aldosterone 
levels (34). This is caused by a mutation of the epithelial sodium channel of the 
distal nephron. 
 
 Renal diseases:  
Renal parenchymal diseases are the most common cause of secondary 
hypertension. Increased intravascular volume or increased activity of the renin – 
angiotensin – aldosterone system is the cause.  
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Renal vascular hypertension: 
  Renal artery stenosis is present in 1 to 2% of all the hypertensive patients 
of the world. Atherosclerosis is the most common cause but in women below 50 
years fibromuscular dysplasia should be suspected. 
 
 The mechanism of hypertension in these patients is due to excessive renin 
release due to decrease in renal perfusion pressure. In single kidney disease or 
bilateral lesion patient’s decreased natriuresis contributes to hypertension. 
Activation of the renal sympathetic nerves is also important.  
 
Renal vascular hypertension should be suspected when 
1) when hypertension develops before age 20 or after age 50 years. 
2) when hypertension is resistance to three or  more antihypertensive drugs. 
3) if epigastric or renal artery bruits are felt 
4) in atherosclerotic diease of the aorta or peripheral arteries 
5) if there is an abrupt increase  in the level of  serum creatinine after giving  
angiotensin – converting enzyme (ACE) inhibitors, or 
6) if episodes of pulmonary edema with abrupt increase in blood pressure are 
seen. 
 
 There is no ideal screening test for renal vascular hypertension. If suspicion 
is high renal arteriography is the definitive diagnostics test. Where suspicion is 
moderate to low, noninvasive angiography using magnetic resonance (MR) or CT 
can be done(44).  
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Doppler sonography has good specificity but lacks sensitivity. Contrast 
agent gadolinium used in MR angiography is contraindicated in patient when 
estimated glomerular filtration rate  (eGFR) is less than 30 ml / min. But in young 
patients with fibromuscular disease, angioplasty is very effective.  
 
Correction of the stenosis in some patients will reduce the number of 
medications required to control blood pressure and protect the kidney function. 
 
 The extent of preexisting parenchymal damage of the affected and 
contralateral kidney will have a significant influence on both blood pressure and 
kidney function out comes following revascularization(33). 
 
 Angioplasty and stenting may be superior to medical therapy in some 
patients. A reasonable approach always is to continue medical therapy as long as 
hypertension can be well controlled and there is no progression of kidney 
diseases. A statin should always be added to the treatment regime.  
 
Endovascular intervention should be considered in patients only when 
uncontrollable hypertension, progressive kidney diseases, or episodic pulmonary 
edema are present (50). 
 
 However, multiple studies have failed to identify the overall advantage of 
stenting over antihypertensive medical management in patients with 
atherosclerotic renal artery stenosis. Although many drugs modulating the renin-
angiotensin system have improved the success rate of medical management of 
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hypertension due to renal artery stenosis, still they may trigger hypotension and 
kidney dysfunction in persons with bilateral diseases.  
 
Primary hyperaldosteronism:-  
Hyperaldosteronism is suggested when the plasma aldosterone 
concentration is high and low plasma renin activity. However the plasma 
aldosterone/ renin ratio is not a screening test for primary hyperaldosteronism.  
 
Adrenal adenoma or bilateral adrenal hyperplasia is responsible for 
hyperaldosteronism associated in patients with secondary hypertension. Screening 
is always done in patients with resistant hypertension and in those with 
spontaneous or thiazide-induced hypokalemia or family history of primary 
hyperaldosteronism.  
 
While evaluating for hyperaldosteronism, drugs that alter renin and 
aldosterone levels such as ACE inhibitors, angiotensin receptor blockers, 
diuretics, beta blockers and clonidine should be discontinued for two weeks(17). 
Spironolactone and eplerenone should be held for 4 weeks. 
 
 Patients can be treated with Calcium Channel and alpha receptor blockers 
to control blood pressure during this drug wash out period. Patients with a plasma 
aldosterone levels greater than 16ng/dl and an aldosterone/renin ratio of 30 or 
more might require further evaluation for primary hyperaldosteronism. 
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Cushing Syndrome: 
About 80% of patients with cushing syndrome will have hypertension. 
Excess glucocorticoid is the cause along with increased salt and water retention 
due to increased angiotension level. 
 
Pheochromocytoma: 
Pheochromocytoma is an uncommon disease and is found in less than 0.1% 
of all the hypertensive patients in the world. However autopsy studies indicate 
that pheochromocytoma are very often undiagnosed in life. 
 
 Blood pressure elevation in pheochromocytoma is caused due to excessive 
catecholamines which results in vasoconstriction of arterioles, and increased in 
cardiac output and renin release. Hypertensive crisis in pheochromocytoma may 
be precipitated by a variety of drugs including tricyclic antidepressant, anti 
dopaminergic agents, metoclopramide and naloxone(52). 
 
Coarctation of the aorta: 
 Evidence of radial femoral delay should be sought in all younger patients 
with hypertension. 
 
Hypertesion associated with pregnancy: 
Hypertension occurring or worsening during pregnancy including 
preeclampsia and eclampsia is one of the major and common causes of maternal 
and fetal morbidity and mortality. Auto antibodies which activate the angiotensin 
II type 1 receptor have been implicated in preeclampsia patients(48). 
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Estrogen use: 
A slight increase in blood pressure occurs in most women taking oral 
contraceptives. However a more significant increase in blood pressure of above 
140/90mmHg is noted in about 5% of obese women older than age 35 years and 
who have been treated for more than 5 years(24). This is due to increased hepatic 
synthesis of angiotensinogen. Postmenopausal esterogen usually does not cause 
hypertension’ 
 
Other causes of Secondary Hypertension:- 
 Hypertension has also been associated with hypercalcemia, acromegaly, 
hyperthyroidism, hypothyroidism, baroreceptor denerbation, compression of the 
rospralventrolateral medulla and increased intracranial pressure(43). Some drugs 
may cause hypertension such as cyclosporine, tacrolimus, decongestant, NSAIDs, 
cocaine and alcohol. 
 
When to refer: 
 Referral to a hypertension specialist should always be considered in case of 
severe resistant or early / late onset hypertension or when secondary hypertension 
is suggested by screening.  
 
 Only in a small minority of patients with elevated arterial pressure, can a 
specific cause be identified. These individuals will probably have an endocrine or 
renal defect that, if corrected, pressure will come back to normal value (51).  
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PATHOPHYSIOLOGY: 
 Hypertension is a wildly prevalent disease and a major risk factors for 
adverse CVS events including CAD, PVD, HF and CKD. Studies show there is a 
continues relationship between high blood pressure and adverse cardiovascular 
outcomes including death. Previously high diastolic blood pressure was the 
indicator for initiating anti-hypertensive treatment but now even elevated systolic 
blood pressure alone is also sufficient enough to start anti-hypertensive treatment, 
particularly in elderly people.  
 
 One of the major obstacles in the treatment of hypertension is the largely 
asymptomatic nature of the disease, even in patient with marked elevation in 
systolic blood pressure. This disconnect between symptoms and long term adverse 
consequences has earned hypertension the designation “silent killer”. Some 
people begin to exhibit symptoms only after doing exercises. In this type of 
people hypertension put them at major risk for developing coronary artery disease, 
stroke and heart failure. Thus, effective strategies for detection and management 
of hypertension are critical elements in the primary and secondary prevention of 
cardiovascular diseases.  
 
Fortunately there are many number of drugs available to treat patient with 
hypertension.  These drugs can be given initially as a single drug. However the 
progressive nature of hypertension characteristically leads to the use of multi drug 
treatment (28). Although the clinical end points of treatment can vary from patient 
to patient, the principle aim of treatment of hypertension is to reduce the measured 
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blood pressure below  140 mm Hg mercury for systolic and less than 90 mm Hg 
for diastolic blood pressure. 
 
 Clinically hypertension has been categorized as primary or secondary 
hypertension. Essential hypertension is the one in which the cause of elevated 
blood pressure is unknown in 90-95% of the hypertensive population. The cause 
of essential hypertension more likely multi factorial, including both genetic 
factors and environmental factors such as alcohol consumption, obesity and high 
salt intake (33). Secondary hypertension refers to patient in whom increased blood 
pressure can be due to a defined cause. Example of secondary hypertension 
includes primary hyperaldosternism, use of oral contraception, intrinsic renal 
diseases and renovascular diseases.  
 
 Blood pressure is usually determined by the product of heart rate, stroke 
volume and systemic vascular resistance. Heart rate is mainly determined by 
sympathetic activity. Preload, afterload and contractility of heart determines 
stroke volume. Systemic vascular resistance reflects the aggregate vascular tone 
of the arteriole subdivision of the systemic circulation. The pharmacological 
approach to the treatment of both primary and secondary hypertension requires an 
understanding of the physiology of normal blood pressure regulation and the 
mechanism that could be responsible for hypertension in individual patients. 
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CARDIAC FUNCTION: 
 One important mechanism for persistence high blood pressure is due to 
primary elevation in cardiac output (‘high output’ hypertension).  A ‘hyperkinetic’ 
circulation can occur due to excessive sympathoadrenal activity and / or increased 
sensitivity of the heart to basal levels of neurohumoral regulaters. The 
hemodynamic pattern of pump based hypertension (ie, increased cardiac output 
(CO) with normal systemic vascular resistance (SVR) is most often seen in 
younger patients with essential hypertension. This pattern can then affect vascular 
wall tone and then hemodynamic profile in which the principle cause of disease 
appears to shift to the peripheral vasculature. This high output hypertension 
patients are treated with β – adrenoceptive antagonist.  
 
VASCULAR FUNCTION: 
 Vascular resistance based hypertension (ie normal CO with increased 
SVR) is a common mechanism underline hypertension in the elderly people. In 
individuals with this form of hypertension, it is hypothesized that the vasculature 
is abnormally responsive to sympathetic  stimulation, circulating factors or local 
regulation of vascular tone.  The abnormal responsiveness of the vasculature may 
be mediated in parts by endothelial damage or dysfunction, which is known to 
disrupt the normal equilibrium between local vasodialating (eg. Nitric oxide) and 
vasoconstructive (eg. Endothelin ) factors. In addition ion channel defects in 
vascular smooth muscle can cause abnormal elevation in basal vasomotor tone 
that result in increased systemic vascular resistance(28). Vascular resistance – 
based hypertension may present as a predominant elevation of systolic blood 
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pressure. Studies have demonstrated the effectiveness of thiazide diuretic in this 
population making such agents the preferred initial treatment. 
 
RENAL FUNCTION: 
 Abnormalities of renal function can lead to the development of systemic 
hypertension. Volume based hypertension develops due to excessive retention of 
sodium and water. Glomerular injury caused by renal parenchymal disease will 
reduce functional nephron mass and/ or excessive secretion of renin which will 
lead to abnormal increase in intra vascular volume (42). 
 
 Sometimes, ion channel mutation can impair normal sodium excretion. 
Decreased renal blood flow due to renal vascular diseases (eg. Renal artery 
stenosis fibromuscular dysplasia, vasculitis or external compression) will lead to 
decreased perfusion pressure of kidneys. Decreased perfusion will lead to 
excessive secretion of renin by juxtaglomerular cells, which in turn lead to 
increased production of angiotension II and aldosterone (62). This will increase 
vasomotor tone and Na+ and H2O retension, leading to a hemodynamic profile in 
which both CO and SVR increased.  
 
NEUROENDOCRINE FUNCTION: 
 Abnormal function of the endocrine system including dysfunction of 
central regulation of basal sympathetic tone, atypical stress response, abnormal 
responses to signals from baroreceptors and intravascular volume receptors and 
excessive production of hormones that act to regulate the circulation can alter 
cardiac, vascular and/ or renal functions leading to increased systemic blood 
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pressure(35). Example of endocrine abnormalities associated with systemic 
hypertension include excessive secretion of aldosterone by the adrenal cortex 
[primary aldosterone] and excessive production of thyroid hormone 
(hyperthyroidism). 
 
 Most of the secondary mechanisms associated with hypertension are 
generally fully understood, and are outlined as secondary hypertension. 
 
 However, those associated with essential (primary) hypertension are far 
less understood. What is known is that cardiac output is raised early in the disease 
course, with total peripheral resistance (TPR) normal(42).  After sometime the time 
cardiac output drops to normal level but TPR is increased.  
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Three theories have been proposed to explain this: 
Theory 1: 
 Inability of the kidneys to excrete sodium resulting in nateriuretic factor 
such as Atrial Natriuretic Factor being secreted to promote salt excretion with the 
side effects of raising total peripheral resistance. 
 
Theory 2: 
 An overactive renin – angiotension system leads to vasoconstriction and 
retention of sodium and water. The increased in blood volume leads to 
hypertension. 
 
Theory 3:  
 An overactive sympathetic nervous system leading to increased stress 
responses. It is also known that hypertension is highly heritable and polygenic 
(caused by more than one gene) and a few candidate genes have being postulated 
in the etiology of the condition.  
 
APPROACH TO NEWLY DIAGNOSED HYPERTENSION: 
 Hypertension patients are usually asymoptomatic and they are diagnosed 
usually by routine examination or when a complication arises. 
 
The objective of the intial evaluation of patients with high BP reading are  
 To obtain accurate blood pressure measurement  
 To identify any underlying cause and contributory factors. 
 To access other risk factor especially cardiovascular risk. 
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 To detect any complication those are already present eg: end organ 
damage. 
 To identify any comorbidity that may influence the choice of 
antihypertensive therapy.        
 
 These are attained by careful history taking, clinical examination and some 
simple investigation. 
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BLOOD PRESSURE MEASUREMENT: 
Blood pressure is recorded usually in sitting position. The reading at which 
the sounds are first heard is taken as systolic pressure. The pressure reading at 
which the sounds disappear is taken as diastolic pressure. Both systolic and 
diastolic pressures should be measured at least three times. Of the three readings 
the lowest reading should be noted. 
 
MAGNITUDE OF THE PROBLEM: 
Even though blood pressure can be measured easily, it took several years to 
realize that this arterial hypertension is a frequent and major worldwide health 
problem(18).  
 
INCIDENCE: 
 World wide , it was estimated that high blood pressure caused more than 
7.5 million deaths that is above 12.8 percent of the total of all annual deaths. 
Hypertension is a major risk factor for ischaemic heart diseases and coronary 
heart diseases as well as hemorrhagic strokes. Other complications due to 
persistence raised blood pressure are heart failure, peripheral vascular disease, 
renal impairment, visual impairment and retinal hemorrhage. Reducing systolic 
and diastolic blood pressure below 140/90 is associated with a reduction in cardio 
vascular complications(22). The prevalence of raised blood pressure is around 40% 
for both sexes and also in low, lower middle and upper middle – income 
countries. In high income countries it is above 35% for both sexes. 
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PREVALENCE IN INDIA: 
 Prevalence of hypertension is above 17 to 21 % throughout India. Even 
though hypertension was prevalent in all educational levels it is much higher in 
higher educational level of states in India such as Kerala and Tamilnadu. 
 
PREVENTION OF HYPERTENSION 
PRIMARY PREVENTION: 
 Eventhough control of hypertension can be achieved by medication the 
ultimate goal in general is primary prevention. Primary prevention has been 
defined as “all measures to reduce the incidence of disease in a population by 
reducing the risk of onset “  
 
Non pharmacotherapeutic intervention to reduce arterial hypertension are; 
 Reduction of salt intake that is less than 5gm /day 
 Reduction in  fat intake  
 Avoidance of high alcohol intake  
 Weight reduction  
 Physical exercise   
 Behavioral changes such as reduction of stress and quitting smoking, life 
style modification , and doing yoga and taking medications   
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SECONDARY PREVENTION: 
 To detect and control high blood pressure in affected individual is the goal 
of secondary prevention. 
 
 Early reduction of hypertension is a major problem because most of the 
patients are asymptomatic until an organ damage has occurred. Therefore 
screening is the only effective method of diagnosis of hypertension. 
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TREATMENT 
 In essential hypertension, we cannot treat the cause because we do not 
know what is the cause for high blood pressure. Instead we try to bring down the 
persistently high blood pressure to normal levels. The main objective of treatment 
is to get a blood pressure below 140/90, because control of hypertension as shown 
to reduce the incidence of stroke and other complication. Therefore it is important 
to treat asysmptomatic patients. 
 
DRUGS USED IN HYPERTENSION 
 
CLASSIFICATION 
Diuretics 
Thiazides: Hydrochlorothiazide, 
Chlorthalidone, Indapamide 
High ceiling: Furosemide, etc. 
K+ Sparing: Spironolactone, Amiloride. 
 
ACE inhibitors 
Captopril, Enalapril, Lisinopril, 
Perindopril, Ramipril, Fosinopril, etc. 
Angiotensin blockers 
Losartan, Candesartan, Irbesartan, Valsartan, 
Telmisartan 
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Direct renin inhibitor 
 Aliskiren 
 
Calcium channel blockers 
Verapamil, Diltiazem, Nifedipine, Felodipine, 
Amlodipine, Nitrendipine, Lacidipine, etc. 
 
β Adrenergic blockers 
 Propranolol, Metoprolol, Atenolol, etc. 
 
β + α Adrenergic blockers 
Labetalol, Carvedilol 
 
α Adrenergic blockers 
Prazosin, Terazosin, Doxazosin 
Phentolamine, Phenoxybenzamine 
 
Central sympatholytics 
 Clonidine, Methyldopa 
 
Vasodilators 
 Arteriolar: Hydralazine, Minoxidil, 
 Diazoxide 
 Arteriolar + venous: Sodium nitroprusside 
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DIURETICS 
Diuretic is standard antihypertensive drugs over the past few decades. They 
do not lower BP in normotensives patients. Thiazides are the diuretic of choice for 
uncomplicated hypertension. Chlorthalidone is much longer acting than compared 
to hydrochlorothiazide and may have twenty four hour action. The 
antihypertensive mechanism of action of diuretics is: 
 
1. First, they lowers plasma and e.c.f. volume by 5–15%, and this lead to 
decrease in c.o. 
2. Subsequently, compensatory mechanisms operate to regain   Na+ balance 
and plasma volume so that c.o. is restored. But the fall in BP is maintained 
by a slowly developing reduction in t.p.r. 
3. The reduction in t.p.r. is most due to an indirect consequence of a small 
persisting Na+ and volume deficit. This decrease in intracellular Na+ 
concentration in the vascular smooth muscle may reduce stiffness of blood 
vessel wall, increase their compliance and inhibits responsiveness to 
constrictor stimuli.  Similar effects are also produced by salt restriction so 
antihypertensive action of diuretics is lost when salt intake is high in the 
diet. 
 
 Thiazides have mild antihypertensive action, average fall in mean arterial 
pressure is less than10 mm Hg. They are effective by themselves in less than 30% 
cases (mostly low grade hypertension) but they potentiate all other 
antihypertensive drugs (except DHPs) and prevent development of tolerance to 
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other antihypertensive drugs. Hence, in combination, they are useful in any grade 
of hypertension. They are mostly used in the elderly patients and maximal 
antihypertensive efficacy is reached at dose of 25 mg/day. 
 
 High ceiling diuretics Furosemide, is a strong diuretic, but it as a weaker 
antihypertensive effect than thiazides: The explanation to this paradox may lie in 
its brief duration of action of furusemide. The natriuretic action of furosemide 
lasts only 4–6 hr after the conventional morning dose and it is followed by 
compensatory increase in proximal tubular reabsorption of Na+. Furosemide 
diuretics are more liable to cause fluid and electrolyte imbalance, weakness and 
other side effects. They are indicated in treatment of hypertension only when it is 
complicated by: 
 
(a) Chronic renal failure were thiazides are ineffective, both as diuretic and as an 
antihypertensive drug. 
(b) Coexisting refractory CHF. 
(c) Resistance to combination antihypertensive drug regimens containing a 
thiazide, or marked fluid retention due to use of potent vasodilators.  
 
Desirable properties of thiazide diuretics as antihypertensives are: 
1. They can be used as a once a day dosing 
2. No fluid retention, no tolerance develops. 
3. They are effective in isolated systolic hypertension (ISH). 
4. They reduce the risk of hip fracture in the elderly due to hypocalciuric 
action of thiazides and low cost. 
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The draw backs of diuretics are 
 Hypokalaemia 
 Erectile dysfunction 
 Carbohydrate intolerance  
 Dyslipidemia  
 Hyperuricaemia 
 Increased incidence of sudden cardiac death. 
 
 Consequently, prescribing of diuretics for antihypertension decreased. But 
over the past 25 years thiazides have been used successfully at lower doses that is 
(12.5–25 mg/day Hydrochlorothiazide) alone or in combination with a K+ sparing 
diuretic. 
 
Findings with low dose thiazide therapy are: 
 Even though serum K+ level falls a little, significant hypokalaemia does 
not occur. 
 Continuous ECG recording studies have also failed to document increased 
occurrence of arrhythmias during low-dose thiazide therapy. 
 Impairment of glucose tolerance or increase in serum cholesterol or 
hyperuricaemia over long-term are very minimal. 
 Overall mortality and morbidity is very much reduced in long-term trials. 
 Though they are not as effective as ACE inhibitors in reversing left 
ventricular hypertrophy, some recent trials in mild to moderate 
hypertension have found thiazides also reduce left ventricular mass.  
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 The JNC 7 also recommends starting low-dose (12.5–25 mg) thiazide 
therapy, preferably with added K+ sparing diuretic, as a first choice treatment of 
essential hypertension, especially in the elderly. If the low dose thiazide (25 
mg/day) fails to reduce blood pressure to desired level then another 
antihypertensive should be added, rather than increasing dose of the thiazide. 
Potassium sparing diuretics. 
 
 Spironolactone, eplerenone and amiloride lowers BP slightly. However, 
they are used only in combination with a thiazide diuretic to prevent K+ loss. 
They are used especially in refractory hypertension. 
 
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS 
 The ACE inhibitors are the first choice drugs in all grades of essential as 
well as renovascular hypertension. Most patients require lower doses, which are 
very well tolerated. Used alone they control hypertension in more than 50% 
patients. 
 
 ACE inhibitors will increase renal blood flow and retard diabetic 
nephropathy and regress left ventricular/vascular hypertrophy. They are the drug 
of choice in patients with diabetes, nephropathy and left ventricular hypertrophy, 
CHF, angina and post MI cases.  
 
They are more effective in younger (< 55 year) hypertensives than in the 
elderly hypertensive patients. Dry persistent cough is the most common side 
effect. 
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ANGIOTENSIN RECEPTOR BLOCKER 
 In a dose of 50 mg/day losartan is very effective antihypertensive drug. 
Action starts early and reaches peak at 2–4 weeks. Addition of 12.5 mg/day 
hydrochlorothiazide further increase the fall in BP.  
 
The newer ARBs— such as valsartan, candesartan, irbesartan and 
telmisartan have been shown to be as effective antihypertensives as ACE 
inhibitors. Since ARBs does not increase kinin levels cough does not occur. 
Angioedema, urticaria and taste disturbance are also very rare.  
 
Several interventional endpoint reduction trials like LIFE (2002), VALUE 
(outcomes in hypertensive patients with valsartan or amlodipine, 2004), SCOPE 
(study on cognition and prognosis in the elderly; stroke prevention with 
candesartan in elderly with isolated systolic hypertension, 2004), JLIGHT 
(Japanese losartan therapy intended for global renal protection in hypertensive 
patients, 2004) have attested to the favorable effects of ARBs on morbidity and 
mortality in hypertensive patients. As antihypertensive, use of ARBs has 
outstripped that of ACE inhibitors.  
 
β -ADRENERGIC BLOCKERS 
Beta blockers are mild antihypertensives, they do not significantly lower 
BP in normotensives. Used alone they reduce only little fall in BP. Additional BP 
lowering can be obtained when they are combined with other drugs. The 
hypotensive response to β blockers will develop over 1–3 weeks.  
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The antihypertensive action of most β blockers is maintained over 24 h. So 
they can be used as single daily dose. However there are several contraindications 
to β blockers, including cardiac, pulmonary and peripheral vascular disease.  
 
 Because of absence of postural hypotension, bowel alteration, salt and 
water retention and a low incidence of side effects, and once a day regimen, β 
blockers are first choice drugs recommended by JNC 7 and WHO-ISH, especially 
for young non-obese hypertensives. 
 
 β blockers are considered less effective and less suitable for the older 
hypertensive. Rebound hypertension will occur on sudden discontinuation of β 
blockers. 
 
β +α ADRENERGIC BLOCKERS 
Labetalol is a combined α and β blocker; it reduces t.p.r. and acts faster 
than pure β blockers. It used as an i.v. for rapid BP reduction in hyperadrenergic 
states, cheese reaction, clonidine withdrawal, eclampsia, etc. Oral labetalol 
therapy is mainly restricted to moderately severe hypertension not responding to a 
pure β blocker. 
 
 Carvedilol is a nonselective β + weak selective α1 blocker that produces 
vasodilatation and antioxidant/free radical scavenging properties. Side effects are 
similar to labetalol; liver enzymes may rise in some. 
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α-ADRENERGIC BLOCKERS 
Prazosin is a selective α1 antagonist dilates both resistance and capacitance 
vessels. It produces reduction in t.p.r. and mean BP along with minor decrease in 
venous return and c.o. However, unlike hydralazine, there is little reflex cardiac 
stimulation and renin release during long-term therapy. It decreases central 
sympathetic tone. 
 
 Renal blood flow and g.f.r. are maintained but fluid retention may attend 
fall in blood pressure. Cardiovascular reflexes are not impaired during chronic 
therapy, but postural hypotension and fainting may occur in the beginning—called 
‘first dose effect’.  
 
This may disappears with continued therapy, but may persist in the elderly 
patients. For this reason, prazosin is always started at low dose (0.5 mg) usually 
given at bedtime and gradually increased to twice daily dose till an adequate 
response is achieved.  
 
An oral dose produces peak fall in BP after 4–5 hours and the effect lasts 
for nearly 12 hours. Alpha blockers does not impair carbohydrate metabolism and 
it is suitable for diabetics, but not if neuropathy is present, because postural 
hypotension will be accentuated. 
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 It as a small but favorable effect on lipid profile by lowering LDL 
cholesterol and triglycerides and increasing HDL. 
 Additionally they give symptomatic improvement in coexisting benign 
prostatic hypertrophy. Apart from postural hypotension, other side effects 
are headache, drowsiness, dry mouth, weakness, palpitation, nasal 
blockade, blurred vision and rash. Ejaculation is impaired in males. Fluid 
retention due to prazosin monotherapy may precipitate CHF. 
 
 Prazosin is used as a moderately potent antihypertensive, but is not used as 
a first line antihypertensive drug because fluid retention and tolerance gradually 
develops with monotherapy—necessitating dose increase leading to more side 
effects and risk of developing CHF. It can be added to a diuretic + β blocker in 
those who are not achieving target BP. Terazosin, Doxazosin  are long-acting 
congeners of prazosin with similar properties and are suitable for once daily 
dosing. 
 
CALCIUM CHANNEL BLOCKERS 
  Calcium channel blockers (CCBs) are another class of first line 
antihypertensive drugs.  All 3 subgroups of CCBs, viz. dihydropyridines (DHPs, 
e.g. amlodipine), phenylalkylamine (verapamil) and benzothiazepine (diltiazem) 
are equally efficacious antihypertensives. They lower blood pressure by 
decreasing peripheral resistance without compromising cardiac output. Despite 
vasodilatation, fluid retention is insignificant. 
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Ankle edema that occurs in some patients on CCBs is due to increased 
hydrostatic pressure across capillaries of the dependent parts as a result of reflex 
constriction of post capillary vessels in these vascular beds. The onset of 
antihypertensive action of CCBs is quick.  
 
With the availability of long acting preparations, these drugs can be 
administered once a day dose. Monotherapy with CCBs is effective in 50% 
hypertensives; their action is independent of patient’s renin status, and they may 
improve arterial compliance. Other advantages of CCBs are: 
 
1. No impairment of physical work capacity. 
2. No sedation or other CNS effects, cerebral perfusion is maintained. 
3. Not contraindicated in asthma, angina (especially variant) and PVD 
patients and may benefit these conditions. 
4. Do not impair renal perfusion. 
5. Do not affect male sexual function. 
6. No deleterious effect on plasma lipid profile, uric acid level and electrolyte 
balance. 
7. Shown to have no/minimal effect on quality of life. 
8. No adverse fetal effects and can be used during pregnancy (but can weaken 
uterine contractions during labour). 
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 The CCBs do not decrease venous return. DHPs may even increase it and 
jeopardize hemodynamic in patients with diastolic dysfunction. DHPs (especially 
short-acting) also tend to increase HR and c.o. by invoking reflex sympathetic 
stimulation.  
 
The increased mortality among coronary heart disease patients has been 
due to repeated surges of adrenergic discharge and marked swings of blood 
pressure attending each dose of rapidly acting DHP. However, this risk can be 
overcome with slow acting DHPs.  
 
The Hypertension optimal treatment (HOT), and Swedish trial in old 
patients with hypertension-2 (STOP- 2) studies have also found CCBs equi-
effective as diuretics/ β blockers/ACE inhibitors in reducing cardiovascular/total 
mortality. On the other hand, CCBs do not afford survival benefit in post MI 
patients as β blockers, ACE inhibitors or low dose thiazides do. 
 
 CCBs are also not as effective in suppressing left ventricular hypertrophy 
as ACE inhibitors.  But still CCBs continue to be used as one of the first line 
monotherapy options because of their high efficacy and excellent tolerability. 
They are preferred in the elderly hypertensive. The long-acting DHPs are next to 
ACE inhibitors in reducing albuminuria and slowing disease progression in 
hypertensive/ diabetic nephropathy.  
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Use of rapid acting oral nifedipine for urgent BP lowering in hypertensive 
emergencies is out dated. In fact, there is currently no therapeutic indication for 
rapid and short-acting oral DHPs in hypertension. Other concerns in the use of 
CCBs as antihypertensive are: 
 
(i) The negative inotropic/dromotropic action of verapamil/diltiazem may 
worsen CHF and cardiac conduction defects (DHPs are less likely to do 
so). 
(ii) By their smooth muscle relaxant action, the DHPs can worsen 
gastroesophageal reflux. 
(iii) CCBs (especially DHPs) may accentuate bladder voiding difficulty in 
elderly males. 
 
TREATMENT OF HYPERTENSION 
The aim of antihypertensive therapy is to prevent morbidity and mortality 
associated with persistently raised BP by lowering it to an acceptable level, with 
minimum inconvenience to the patient. Both systolic and diastolic BP predicts the 
likelihood of target organ damage (TOD) and complications such as: 
 
a) Cerebrovascular disease, transient ischaemic attacks, stroke, 
ncephalopathy. 
b) Hypertensive heart disease - left ventricular hypertrophy, CHF. 
c) Coronary artery disease, angina, myocardial infarction, sudden cardiac 
death. 
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d) Arteriosclerotic peripheral vascular disease, retinopathy. 
e) Dissecting aneurysm of aorta. 
f) Glomerulopathy, renal failure. 
 
 Patients who have already suffered from TOD have greater risk of further 
organ damage and death at any level of raised BP, than those without TOD. Since 
the risk of complications depends not only on the level of BP, but also on other 
risk factors  and existing TOD, these have also to be considered in deciding when 
to start drug therapy, as well as in selection of drugs and in devising therapeutic 
regimens. 
 
 Beneficial effects of lowering BP have been established in all patients 
having BP above 140/90 mm Hg. In hypertensives having diabetics, lowering 
diastolic BP to 80 mmHg was found to reduce cardiovascular events more than 
reducing it upto 90 mm Hg. 
 
 If the cause of hypertension can be identified such as hormonal, vascular 
abnormality, tumour, renal disease, drugs etc then all efforts should be made to 
remove cause. First nonpharmacological measures such as life style modification, 
Na+ restriction, aerobic activity or exercise, weight reduction, moderation in 
alcohol intake, mental relaxation, etc should be tried along with antihypertensive 
drugs.  
 
The level to which BP should be lowered is not clear. But a value of < 140 
systolic and < 90 mmHg diastolic is considered adequate response to therapy, 
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because it clearly reduces morbidity and mortality. In patients with CAD, heart 
failure, stroke, etc it should be even reduced to 120/80. 
 
 Efficacy wise all the 4 classes of drugs are equal . But the drug for initial 
therapy is selected on the basis of suitability criteria taking into consideration of 
the patients age, life style issues, risk factors, concomitant medical conditions, 
tolerability in respect of the individual patient and cost of different drugs.  
 
The general principles of antihypertensive therapy enunciated in JNC7, 
WHO-ISH and British Hypertension Society* (BHS) 2004, guidelines may be 
summarized as: 
 
1. Except for stage II hypertension, start with a single drug, which for 
majority of patients it will be thiazide. However, an ACE inhibitor/ARB or 
CCB or in some cases β blocker may also be considered.  
2. The BHS (2004) recommended following the A B C D rule (A—ACE 
inhibitor/ARB; B—β blocker; C—CCB, D—diuretic). While A and (in 
some cases) B are preferred in younger patients (<55 years), C and D are 
preferred in the older older patients (> 55 years). 
3. Start therapy at low dose and then if needed increase dose moderately. 
Thiazide dose should not be more than 12.5–25 mg/day. 
4. If no response then change to a drug from another class, or low dose 
combination from other classes. 
5. If side effect to the initially chosen drug occurs then either substitute with 
drug of another class or reduce dose and add a drug from another class. 
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6. Majority of stage II hypertensives are started on a 2 drug combination and 
one of which usually is a thiazide diuretic. 
 
 With the above approach 50–70% stage I hypertensives can be successfully 
treated, at least initially, with monodrug therapy. Combination therapy Though 
JNC 7, WHOISH and BHS guidelines emphasize on single drug therapy and the 
addition of a second (and third or even fourth) drug is also highlighted when 
monotherapy fails. 
 
 Since BP is kept up by several interrelated factors, an attempt to block one 
of them tends to increase compensatory activity of the others. So it is rational in 
such cases to combine drugs with different mechanisms of action or different 
patterns of hemodynamic effects: 
 
a) Drugs which increase plasma renin activity— diuretics, vasodilators, 
CCBs, ACE inhibitors may be combined with drugs which lower plasma 
renin activity—β blockers, clonidine, methyldopa. 
 
b) All sympathetic inhibitors (except β blockers) and vasodilators, except 
CCBs, cause fluid retention leading to tolerance. Addition of a diuretic 
checks fluid retention and development of tolerance. 
 
c) Hydralazine and DHPs cause tachycardia which is counteracted by β 
blockers, while the initial increase in t.p.r. caused by nonselective β 
blockers is counteracted by the vasodilator. 
 
43 
 
 
d) ACE inhibitors/ARBs are particularly synergistic with diuretics; this 
combination is very good for patients with associated CHF or left 
ventricular hypertrophy. 
 
e) In step 2 when two drugs are to be used, the BHS recommend combining 
one out of A or B with one out of C or D. 
 
f) Use of combined formulation improves compliance and usually lowers 
cost. 
 
g) In the step 3 (when two drugs are inadequate in achieving target BP 
lowering), triple drug regimen is prescribed. Both C and D are combined 
with A or B, whereby large majority of patients are adequately controlled. 
 
h) Patients who fail to reach the goal BP despite being adherent to full doses 
of an appropriate 3 drug (including a diuretic) regimen have been labeled 
by JNC7 as ‘resistant hypertension’. In them even 4 drug therapy step 4 
may have to be given to achieve the target BP. However, the patient must 
be reevaluated and factors like non-compliance, pseudo tolerance, need for 
a loop diuretic, drug interactions, secondary hypertension, etc. must be first 
excluded. All four first line drugs are used together, or an α1 blocker is 
included with 3 first line drugs. Eplerenone also is being used as the 4th 
drug now. Hydralazine or clonidine  are rarely included. 
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Combinations to be avoided 
1. An α or β adrenergic blocker with clonidine: apparent antagonism of 
clonidine action has been observed. 
2. Hydralazine with a DHP or prazosin; because of similar pattern of 
hemodynamic action. 
3. Verapamil or diltiazem with β blocker, because marked bradycardia, A-V 
block can occur. 
4. Methyldopa with clonidine or any two drugs of the same class. 
 
 When the BP has been well controlled for > 1 year, stepwise reduction in 
dose and/or withdrawal of one or more components of a combination may be 
attempted to work out a minimal regimen that will maintain the target BP. 
However, in most patients of essential hypertension, drug therapy is usually life-
long. 
 
Hypertension in pregnancy  
 A sustained BP reading above 140/90 mm Hg during pregnancy has 
delirious effect on both mother and the foetus therefore reduction of BP clearly 
reduces risks 
 
Two types of situations are possible:  
a) A woman with preexisting essential hypertension becomes pregnant. 
b) Pregnancy induced hypertension; as in toxaemia of pregnancy—
preeclampsia. 
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 Toxaemic hypertension is associated with a hyperadrenergic state, decrease 
in plasma volume (despite edema) and increase in vascular resistance. In the first 
category the same therapy instituted before pregnancy may be continued.  
 
Antihypertensives to be avoided during pregnancy 
 ACE inhibitors, ARBs will produce Risk fetal damage, growth retardation. 
Diuretics drugs tend to reduce blood volume and worsen uteroplacental perfusion 
deficit (of toxaemia)—increase risk of fetal wastage, placental infarcts, 
miscarriage, stillbirth. 
 
 Nonselective β blockers, Propranolol has been implemented to cause low 
birth weight, decreased placental size, neonatal bradycardia and hypoglycaemia. 
 
 Sod. Nitroprusside is contraindicated in eclampsia. Antihypertensives 
found safer during pregnancy are labetalol and Methyldopa. Dihydropyridine 
CCBs if used, should be discontinued before labour as they weaken uterine 
contractions. 
 
Hypertensive emergencies and urgencies 
 Systolic BP > 220 or diastolic BP > 120 mm Hg with evidence of active 
end organ damage is labelled ‘hypertensive emergency’, while the same elevation 
of BP without overt signs of end organ damage is termed ‘hypertensive urgency’. 
Severity and rate of progress of TOD determines the seriousness of the condition. 
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Controlled reduction of BP over minutes (in emergencies) or hours (in urgencies) 
is required to counter threat to organ function and life in: 
1. Cerebrovascular accident (hemorrhage) or head injury with high BP. 
2. Hypertensive encephalopathy. 
3. Hypertensive acute LVF and pulmonary edema. 
4. Unstable angina or MI with raised BP. 
5. Dissecting aortic aneurysm. 
6. Acute renal failure with raised BP. 
7. Eclampsia. 
8. Hypertensive episodes in pheochromocytoma, cheese reaction or clonidine 
withdrawal. 
 
Oral therapy 
 Some rapidly acting oral hypotensive drugs have been used in hypertensive 
urgencies, but now they are considered neither necessary nor safe. 
 
 Nifedipine (10 mg soft geletine cap.) orally or s.c. every 30 min was 
widely employed in urgencies. This practice has now been abandoned because it 
often causes abrupt fall in BP and precipitates MI or stroke, or may be fatal. Once 
the drug is ingested, rate and degree of fall in BP cannot be controlled, and 
adverse consequences outweigh its advantages. 
 
 Captopril (25 mg oral every 1–2 hours) was also used, but response is 
variable and it carries risk of excessive hypotension. 
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 Clonidine (100 μg every 1–2 hours oral) acts mostly in 30–60 min, but 
produces sedation and rebound rise in BP on stopping the drug. 
 
Parenteral therapy 
 Parenteral (preferably i.v.) drugs with controllable action are used both in 
emergencies and in urgencies (less vigorously in the latter). However, many 
studies consider that in the absence of end organ damage (urgencies), i.v drugs are 
not necessary. But slow reduction of BP with oral drugs is adequate and safer. 
 
 Mean BP should be lowered by no more than 25% over a period of minutes 
or a few hours and then gradually to not lower than 160/100 mm Hg. 
 
Drugs employed are: 
1. Sodium nitroprusside because of its predictable, instantaneous, titratable and 
balanced arteriovenous vasodilatory action. Nitroprusside (20–300 μg/min) is 
the drug of choice for most hypertensive emergencies. However, it is toxic in 
high dose and when used for longer period of time. GTN may be better choice 
when there is associated MI or LVF. In aortic dissection, nitroprusside  as to 
given with esmolol infusion. Another limitation with nitroprusside is that it 
needs an infusion pump and constant monitoring. 
 
2. Glyceryl trinitrate when given by i.v. infusion (5–20 μg/min) acts within 2–5 
min and has brief titratable action, but it is a less potent hypotensive. Its 
predominant venodilator action makes it particularly suitable for lowering BP 
after cardiac surgery and in acute LVF, MI, unstable angina, but not in other 
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conditions. Disadvantage is tolerance starts developing after 18–24 hours of 
continuous infusion. 
 
3. Hydralazine 10–20 mg i.m. or slow i.v. injection acts within 20–30 min and 
keeps BP low for 4–8 hours, but is less predictable, and not a first line drug. It 
has been especially used in eclampsia. It produces tachycardia and should be 
avoided in patients with myocardial ischaemia or aortic dissection. 
 
4. Esmolol this β blocker given as 0.5 mg/kg bolus followed by slow i.v. 
injection (50–100 μg/kg/min) acts within 1–2 min and action lasts for 10–20 
min. It is useful when cardiac contractility and work is to be reduced, such as 
in aortic dissection.  
 
Nitroprusside is given concurrently, because the BP lowering action of 
Esmolol is weak. It is a useful hypotensive and bradycardiac drug during and 
after anesthesia. Excess bradycardia is to be guarded. 
 
5. Phentolamine this nonselective α1 + α2 blocker is the drug of choice for 
hyperadrenergic states, e.g. hypertensive episodes in pheochromocytoma, 
cheese reaction or clonidine withdrawal. Injected i.v. (5–10 mg) it acts with in 
2 min and action lasts for 5–15 min. Tachycardia and myocardial ischaemia 
may complicate its use. A β blocker may be added along with this. 
 
6. Labetalol Injected i.v. is an alternative to an α blocker + a β blocker 
combination for lowering BP in pheochromocytoma, etc. but has only weak α 
blocking action. It has been used to lower BP in MI, unstable angina, 
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eclampsia as well. It is also good for patients with altered consciousness, 
because it does not cause sedation or increase intracranial pressure. 
Concomitant CHF or asthma are contraindication for its use its use. 
 
7. Furosemide (20–80 mg oral or i.v.) can be be given as an adjunct with any of 
the above drugs if there is volume overload (acute LVF, pulmonary edema, 
CHF) or cerebral edema (in encephalopathy), but should be avoided when 
patient is in hypovolemic due to pressure induced natriuresis (especially in 
eclampsia, pheochromocytoma). 
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RESVERATROL 
Introduction 
 Resveratrol (RES) is a non-flavonoid polyphenolic compound derived from 
stilbene. It is a phytoalexin produced by plants, and is present more in grapes and 
red wine. It has a potential protective role against CVDs, and be involved in the 
“French paradox” characterized by the low incidence of CVDs in the French 
population in spite of taking high intake of saturated fats, along with moderate red 
wine consumption. 
 
 Therapeutic benefits of moderate red wine consumption have been shown 
by numerous studies to decrease blood pressure. Resveratrol is found in red 
grapes seeds and in plants that can survive harsh environmental condition. EFSA 
has categorized RESV as food supplement so it can be taken without a doctor’s 
prescription or recommendation. 
 
 Resveratrol has a cardioprotection, antidiabetic and neuroprotective effects 
due to its antioxidant properties.  Inaddition  resveratrol has vasoprotective 
properties. RES has a protective action on the vascular walls against oxidation, 
inflammation, platelet oxidation and thrombus formation.  
 
 In vitro, cardioprotective mechanisms of RESV are due to its ability to up 
regulate eNOS. Which in turn shown to improve endothelial function, by 
improving the bioavailability of nitric oxide (NO).  
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Anti-Atherosclerotic Effects of RES 
 Atherosclerosis predominantly affects the intimal layer of the arterial 
vessel wall. Atherosclerosis is characterized by the deposition of extracellular 
lipids, and a chronic inflammation. It further leads to luminal narrowing and/or 
thrombus formation, which in turn leads to coronary artery disease, peripheral 
arterial disease or stroke.  
 
 Some preclinical studies have shown that RES could alter lipid profile by 
decreasing plasma triglyceride and LDL-cholesterol levels, and by increasing 
HDL- cholesterol.  
 
Anti-Hypertensive Effects of RES  
 Hypertension is a major risk factor for CVDs. RES Anti-hypertensive 
effects have been demonstrated in several animal models of hypertension, after 
treatment by 10 to 320 mg RES/kg body weight/day, for 14 days to 10 weeks.  
 
 Many studies shown that relatively low doses of RES (5–10 mg/kg/day) 
significantly decreased blood pressure in animal models having hypertension 
along with insulin resistance. This suggests that RES would be more effective in 
patients with diabetes or metabolic syndrome.  
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 Dolinsky et al. observed that a high dose of RES decreased high pressure 
and prevented cardiac hypertrophy in two hypertensive animal models namely 
spontaneously hypertensive rats and angiotensin-II infused mice. A some studies 
also proved RES as the ability to reverse cardiac hypertrophy and contractile 
dysfunction, which is associated with hypertension. 
 
 In a recent study  it was found that, RES alone is ineffective in reducing 
blood pressure in 28 weeks old spontaneously hypertensive rats, but when given 
in a combination of RES with amlodipine (a blood pressure lowering agent) it was 
more effective than amlodipine monotherapy alone in improving cardiovascular  
parameters. 
 
 The mechanisms involved in the antihypertensive properties of RES are 
endothelium-dependent, with the activation of AMPK (a regulator of energy 
metabolism), SIRT-1 and Nrf2. Which results in a vasodilatation due to improved 
availability of NO, in relation to increased expression and activity of eNOS. 
 
 Endothelium-independent vasodilatation mechanisms  also been reported, 
such as activation of AMPK activation, leading to an inhibition of angiotensin II 
(AngII)-induced phosphorylation of myosin phosphatase-targeting subunit 1 and 
myosin light chain leading to inhibition of vascular smooth muscle contractility .  
 
 Therefore daily treatment with RES decreased hypertension in an 
experimental model of AngII-induced hypertensive mice. The decrease in blood 
pressure is often leads to improvement of metabolic parameters.  
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 Resveratrol when added to a standard anti-hypertensive therapy will 
control blood pressure by increasing the production of Nitric Oxide (NO1 an 
endogenous and potent vasodilator ). Endothelium lining blood vessels will 
produce NO, which facilitates vasodilatation by activating the enzyme guanylate 
cycloxygenase (GC). GC then initiates a signaling cascade, which results in 
relaxation of the smooth muscle layer of blood vessels and produce vasodilatation. 
This vasodilatation reduces peripheral resistance which directly affects arterial 
pressure and lowers blood pressure.  
 
 Resveratrol has been reported to have a dose – dependent anti-hypertensive 
effect in various animal models of systemic hypertension. Resveratrol at a low 
dose of 2.5mg/kg body weight/day has been shown to enhance the effects of other 
anti-hypertensive medication in the spontaneously hypertensive rat models.   
 
 Additionally, resveratrol protects against and or reverse pulmonary 
hypertension in rat. It is also effective in preventing high fat induced and high 
sucrose induced arterial stiffness in non human primates. Resveratrol mediated 
reduction in hypertension has been attributed to various mechanism including 
improvement in oxidative stress, inflammation, endothelial dysfunction and 
vasodilatation.  
 
 Resveratrol have a incremental effect in lowering high BP when taken 
along with the standard anti-hypertensive medication. Resveratrol reduce the 
dosage of anti-hypertensive medication that has side effects.  
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 Relatively low doses of resveratrol (5-10mg /kg/day ) were sufficient to 
lower BP in hypertension animal models associated with Insulin resistance, 
suggesting that resveratrol may be more effective in lowering BP in patients with 
diabetic or metabolic syndrome.  
 
 In another study resveratrol reduced systolic BP in obese rats. Likewise 
resveratrol treatment     (20mg/kg/day) significantly lowered systolic and diastolic 
BP’s in female rats fed with high fat diet, but not in rats fed with normal chew 
diet.  
 
 Since age, diabetes and obesity are important risk factors for endothelial 
dysfunction. Resveratrol will prevent both obesity related and age related declines 
in endothelial function. Resveratrol also suppressed basal superoxide production 
and lipid peroxide levels in the diabetic rats thereby protecting the endothelial 
integrity from diabetes.  
 
 Overall resveratrol protection effect on the vasculature may play an 
important role in the prevention of hypertension and / or in the protection against 
hypertension induced end organ damage in the long term.  
 
 In addition to systemic hypertension resveratrol also shown to decrease 
pulmonary hypertension in some animal studies. Resveratrol improve endothelial 
function, attenuate inflammation and oxidative stress and inhibit proliferation of 
pulmonary artery smooth muscle cells in the models.  
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 In addition, resveratrol has shown to reverse established pulmonary 
hypertension when it was administered 28 days after monocrotaline injection. 
These studies show that resveratrol has multiple beneficial effects on the 
vasculature and may hold promise for the treatment and / or prevention of 
systemic hypertension as well as pulmonary hypertension. 
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AIMS & OBJECTIVES 
 
AIM :  
To evaluate the efficacy and tolerability of Resveratrol as an add on 
therapy to standard treatment in patient with systemic hypertension. 
 
OBJECTIVES: 
 
Primary Objective: 
 To observe the reduction in systolic and diastolic blood pressure. 
 
Secondary Objective: 
 To observe for any adverse effect with the study drug. 
  
Methodology 
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METHODOLOGY 
 
 The study was undertaken in mild to moderate hypertensive patients to find 
out the efficacy and tolerability of resveratrol as an add on therapy to the standard 
anti-hypertensive regimen in the reduction of blood pressure.  
 
 The study was conducted in institute of pharmacology, madras medical 
college, Chennai in collaboration with department of Internal medicine, Rajiv 
Gandhi Government General Hospital, Chennai. 
 
STUDY DESIGN: 
 This study was an open-label, randomized, comparative, prospective, 
parallel group study. 
 
STUDY CENTRE: 
 Hypertension Clinic, 
Department of Internal Medicine, 
Madras Medical College & 
Rajiv Gandhi Government General Hospital, Chennai. 
 
STUDY PERIOD: 
 The study was carried out from November 2016 to December 2017. 
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STUDY DURATION: 
 4 weeks for each patient. 
 
STUDY POPULATION: 
 Patient attending the Outpatient department of Hypertension clinic, 
Department of Internal Medicine, Rajiv Gandhi Government General Hospital, 
Chennai 
 
SAMPLE SIZE: 
 60 patients (30 patients in each group) 
 
STUDY PROCEDURE: 
Inclusion criteria: 
 Patients of either sex 
 Patients in the age group of 18-65 years 
 Patients with mild to moderate hypertension 
(Mild hypertension: systolic blood pressure 140-159 mm Hg  and diastolic 
blood pressure 90-99 mm Hg, Moderate hypertension : systolic blood 
pressure 160-179 mm Hg and diastolic blood pressure 100-109mm Hg) 
 Patients with Body Mass Index (BMI) of 18-25 
 Patients willing to give written informed consent 
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Exclusion criteria: 
 Patients with history of septic arthritis, meningitis, pneumonia 
 Patients with history of pyelonephritis, tonsillitis, otitis media 
 Patients with upper respiratory tract infection 
 Patients with any other active infection 
 Patients with any history of surgery in the recent past 3 months 
 Patients with history of malignancies 
 Patients with history of myocardial infraction 
 Patients with evidence of gastrointestinal tract, renal, endocrine, 
cardiovascular abnormalities and any other major systemic illness 
 Pregnant and Lactating women 
 Patients who cannot comply with the protocol 
 Patients not willing to give written informed consent 
 
 The study commenced after obtaining approval from the Institutional 
Ethical Committee. 
 
ENROLLMENT VISIT: 
 Patients who attended the Outpatient department of Hypertension Clinic, 
Department of Internal Medicine, Rajiv Gandhi Government General Hospital, 
Chennai were explained in detail about the study procedure, purpose and its 
benefits. 
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They were explained about the following: 
The purpose of this study was to 
 Achieve better blood pressure reduction 
 Reduce complications 
 Improve the quality of life in hypertensive patients 
 
 Written informed consent was obtained from patients willing to participate 
in the study, in the prescribed format in the regional language prior to the 
performance of the study procedures. If the patient is illiterate, left thumb 
impression was sought. This was done in the presence of impartial witness. 
Patients advised to come on next day at 8.00A.M on empty stomach for screening 
procedure. 
 
SCREENING (Visit 0): 
 Patients who gave written informed consent for participation in the study 
were screened by detailed medical history, blood pressure monitoring, physical 
and systemic examination, baseline demographic characteristics were recorded. 
Blood was drawn for determining the hematological and serum biochemical tests. 
97 patients were screened. 
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LABORATORY INVESTIGATIONS: 
The following laboratory investigations were done at screening 
1. Complete Hemogram 
a. Hemoglobin 
b. Total WBC count 
c. Neutrophil count 
d. Lymphocyte count 
e. Red Blood Cell count. 
2. Blood Biochemistry 
a. Blood sugar 
b. Blood urea 
c. Serum creatinine 
3. Urine Analysis 
4. ECG 
 
RECRUITMENT AND GROUPING: 
 Among 97 patients screened, 60 patients who fulfilled the inclusion and 
exclusion criteria were recruited for the study. The recruited 60 patients were 
randomized into two groups consisting of 30 patients. 
 
GROUPING: 
 CONTROL GROUP :  Amlodipine 5mg OD 
 TEST GROUP  :  Amlodipine 5mg + Cap. Resveratrol 100mg OD 
  
62 
 
 
STUDY VISITS: 
 VISIT 1 ( Base line ) : 
 Out of 97 patients screened 60 patients with systolic blood pressure in the 
range of 140-179 mmHg and diastolic blood pressure in the range of 90- 
109 mmHg were recruited for the study. The following procedure were 
done at visit I. 
 
Randomization: 
 Randomization into two groups 
o Each group consisting of 30 patients 
o Control group patients were given Amlodipine 5mg OD 
o Test group patients were given Amlodipine 5mg and Resveratrol 
100mg 0D 
o Patients were given medication for four weeks 
o Instructed to come fortnightly to collect the medication 
o Patients were instructed to bring the empty foils at the end of 2 weeks 
to check the patients compliance 
o Patients blood pressure was recoded 
o Detailed medical history and clinical examination was done 
o Patients were advised to report to the investigator as soon as possible in 
case of occurrence of any adverse effects 
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Patients were instructed to report to the investigator in case of 
occurrence of any other illness and intake of other medications for the 
same. 
 
VISIT 2 (At the End of 2ndweek): 
o Patients compliance was checked. 
o Patients blood pressure was recorded. 
o Detailed medical history and clinical examination were done. 
o Blood samples were collected for the routine hematological and 
biochemical parameters. 
o Medications were issued to the patients for 2 weeks. 
o Instructed to come fortnightly to collect the medication. 
o Patients were advised to report to the investigator as soon as possible in 
case of any adverse effects. 
o Patients were instructed to report to the investigator in case of occurrence 
of any other illness and intake of other medications for the same. 
 
VISIT 4 (At the End of 4 weeks) : 
o Patients blood pressure were recorded. 
o Detailed medical history and clinical examination were done. 
o Blood samples were collected for the routine hematological and 
biochemical parameters. 
o Instructed to come fortnightly to collect the medication for 2 weeks. 
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o Patients were instructed to bring the empty foils at the end of 2 weeks to 
check the patients compliance. 
o Patients were advised to report to the investigator as soon as possible in 
case of occurrence of any adverse effects. 
o Patients were instructed to report to the investigator in case of occurrence 
of any other illness and intake of other medications for the same. 
o Patients were instructed to attend the Out Patient department of 
Hypertension clinic to get the medications regularly. 
 
 This study was undertaken to find out the efficacy and tolerability of 
resveratrol as an add on therapy to the standard anti hypertensive in the reduction 
of blood pressure in the patients with mild to moderate hypertension.   
 
RESULTS 
 Out of 97 patients screened, 60 patients who fulfilled the inclusion and 
exclusion criteria were recruited for the study. They were randomized into two 
groups, Group I and Group II, each consisting of 30 patients. 
 
 Group I received standard anti hypertensive treatment amlodipine 5mg OD, 
Group II received resveratrol100mg OD along with amlodipine 5mg OD, for a 
period of one month for each patient. 
 
 Parameters were assessed at the baseline, at the end of 2nd week, and at the 
end of 4th week of study.  60 patients (30 in Group I and 30 in Group II completed 
the study. 
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STATICAL ANALYSIS:  
 Statistical analysis was done using one way anova for comparison between 
groups and bonferonni’s test for multiple comparison. Analysis of adverse events 
was done using Chi – Square test. 
 
Reason for Drop Outs:  
1. In Group I , one patient didn’t turn up after 2 week of study and the remaining 
one patient not willing to continue the study after 3 week 
2. In Group II, two patients didn’t turn up after 2 week of study commencement 
and one patient was not willing to continue in the study after 2 week. 
 
  
Results 
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RESULTS 
 
TABLE 1: MEAN AGE DISTRIBUTION 
 
GROUP NO OF PATIENTS MEAN AGE SD 
CONTROL 30 59.73 9.06 
STUDY 30 61.03 8.81 
p Value 0.5755 
 
Table 1 shows the mean age distribution of both the groups.  
Mean age was similar in both the groups. 
There were no statistically significant differences between the groups. 
 
FIGURE 1: MEAN AGE DISTRIBUTION 
 
Figure 1 is the graphical representation of Table 1. 
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TABLE 2: AGE DISTRIBUTION 
 
AGE IN 
YEARS 
CONTROL GROUP STUDY GROUP 
NO PERCENTAGE NO PERCENTAGE 
45-55 10 33.33% 8 26.66% 
55-65 12 40% 13 43.33% 
65-75 8 26.66% 9 30% 
TOTAL 30 100% 30 100% 
 
Table 2 shows age distribution of both the groups. 
Age group 55-65 had most number of patients in both the groups. 
 
FIGURE 2: AGE DISTRIBUTION 
 
 
Figure 2 is the graphical representation of table 2. 
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TABLE 3: SEX DISTRIBUTION 
 
 CONTROL GROUP STUDY GROUP 
 NO OF PATIENTS PERCENTAGE 
NO OF 
PATIENTS PERCENTAGE 
MALE 14 46.66% 15 50% 
FEMALE 16 53.33% 15 50% 
TOTAL 30 100 30 100 
p VALUE 0.7961 
 
Table 3 shows the sex distribution in both the groups. 
Control group had 46.66% males and 53.33% females while study group had 50% 
males and 50% females. 
There was no significant difference in male and female distribution in both the 
groups(p value=0.7961). 
 
FIGURE 3: SEX DISTRIBUTION 
 
Figure 3 is the graphical representation of Table 3. 
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TABLE 4: SYSTOLIC BLOOD PRESSURE 
GROUP BASELINE MEAN±SD 
4 WEEKS 
MEAN±SD p Value 
CONTROL 150.27±4.53 144.9±4.23 0.0001 
STUDY 151.7±3.74 141.47±3.84 0.0001 
p Value 0.1869 0.0017  
 
Table 4 shows the improvement systolic blood pressure in control and study 
group. Within group analysis showed significant improvement in systolic blood 
pressure both groups at 4 weeks compared to baseline (p value=0.0001). 
Between the groups analysis showed a significant difference at the end of 4 weeks 
p value=0.0017 
 
FIGURE 4: SYSTOLIC BLOOD PRESSURE 
 
Figure 4 is the graphical representation of Table 4. 
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TABLE 5: DIASTOLIC BLOOD PRESSURE 
 
GROUP BASELINE MEAN±SD 
4 WEEKS 
MEAN±SD p Value 
CONTROL 94.36±1.69 85.33±3.46 0.0001 
STUDY 93.8±1.91 83.2±3.81 0.0001 
p value 0.2299 0.0272  
 
Table 5 shows the improvement in diastolic blood pressure in control and study 
group. Within group analysis showed significant improvement in diastolic blood 
pressure in both groups at 4 weeks compared to baseline (p value=0.0001). 
Between the groups analysis showed a significant difference at the end of 4 weeks 
p value=0.0272. 
 
FIGURE 5: DIASTOLIC BLOOD PRESSURE 
 
 
 
Figure 5 is the graphical representation of Table 5. 
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BIOCHEMICAL INVESTIGATIONS 
 
TABLE 6: CONTROL GROUP 
INVESTIGATION BASELINE 4 WEEKS p VALUE 
RANDOM BLOOD 
SUGAR 134.6±6.23 132.23±6.36 0.0828 
UREA 27.5±1.8 26.86±1.67 0.0598 
CREATININE 0.79±0.07 0.80±0.11 0.3183 
 
Table 6 shows the biochemical parameters of control group. 
Statistical analysis within the group did not show any significant difference in 
random blood sugar, urea and creatinine. 
 
TABLE 7: STUDY GROUP 
INVESTIGATION BASELINE 4 WEEKS p VALUE 
RANDOM BLOOD 
SUGAR 133.4±6.23 130±7.57 0.0019 
UREA 27.16±1.44 27.06±1.36 0.639 
CREATININE 0.79±0.07 0.80±0.09 0.3601 
 
Table 7 shows the biochemical parameters of study group. 
Statistical analysis within the group showed significant difference in random 
blood sugar (p =0.0019). 
Statistical analysis within the group did not show any significant difference in 
urea, creatinine. 
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TABLE 8: INCIDENCE OF ADVERSE DRUG REACTIONS 
 CONTROL GROUP STUDY GROUP 
NO OF ADRs 7 5 
 
Table 8 shows the incidence of ADRs in patients of both the groups. 
7 ADRs were reported in control group and 5 ADR were reported in study group. 
 
FIGURE 6: INCIDENCE OF ADVERSE DRUG REACTIONS 
 
 
Figure 6 is the graphical representation of Table 8. 
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TABLE 9: ADVERSE DRUG REACTIONS MONITORING 
ADR CONTROL  GROUP STUDY GROUP 
NAUSEA 1 1 
GASTRITIS 1 2 
MYALGIA 3 - 
PALPITATION 1 - 
PEDAL EDEMA 1 1 
HEADACHE - 1 
 
Table 9 shows the adverse effect profile of both the groups. 
Adverse effects were reported more in control group than in study group. 
Gastritis and myalgia were the most common ADRs. 
 
FIGURE 7: ADVERSE DRUG REACTIONS MONITORING 
 
Figure 7 is the graphical representation of Table 9. 
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TABLE 10: CAUSALITY ASSESSMENT OF ADVERSE DRUG 
REACTIONS- CONTROL GROUP 
ADR Certain Probable Possible Un-likely 
Un-
classified 
Un-
classifiable 
NAUSEA - - 1 - - - 
GASTRITIS - - 1 - - - 
MYALGIA - - 3 - - - 
PALPITATION - - 1 - - - 
PEDAL 
EDEMA - 1 - - - - 
HEADACHE - - - - - - 
 
Table 10 shows causality assessment of individual ADR in control group. 
Causality assessment was done using WHO-UMC causality assessment scale. 
ADRs were categorized as either possible. 
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TABLE 11: CAUSALITY ASSESSMENT OF ADVERSE DRUG 
REACTIONS-STUDY GROUP 
ADR Certain Probable Possible Un-likely 
Un-
classified 
Un-
classifiable 
NAUSEA   1    
GASTRITIS   2    
MYALGIA       
PALPITATION       
PEDAL 
EDEMA  1     
HEADACHE   1    
 
Table 11 shows causality assessment of individual ADR in control group. 
Causality assessment was done using WHO-UMC causality assessment scale. 
ADRs were categorized as either possible. 
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TABLE 12: SEVERITY ASSESSMENT OF ADVERSE DRUG 
REACTIONS BY MODIFIED HARTWIG SIEGEL SCALE 
 
SEVERITY CONTROL GROUP STUDY GROUP 
MILD 7 5 
MODERATE - - 
SEVERE - - 
 
Table 12 shows severity assessment of ADR by modified Hartwig Siegel scale. 
All the ADR in control and study group were mild in severity. 
  
Discussion 
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DISCUSSION 
 
 Hypertension, one of the leading causes of morbidity and mortality in both 
developing and developed countries. Hypertension when untreated, leads to 
various cardiovascular risks such as increased incidence of atherosclerosis, 
coronary artery disease and cerebrovascular risks such as stroke. It has been found 
that high blood pressure have been associated with increased incidence of stroke 
and other cardiovascular risks. 
 
 None of the anti-hypertensive drugs produce nitric oxide levels, which not 
only increases the arterial stiffness but also increases the risk of cardiovascular 
complications such as coronary artery disease and increased incidence of 
cerebrovascular accidents such as stroke. 
 
 Studies suggest that resveratol, a potent anti-oxidant by scavenging free 
radicals prevents the degradation of nitric oxide decreases the constrictor response 
of catecholamines and aids in the reduction of blood pressure. Hence the study 
was undertaken to find out the efficacy and tolerability of resveratrol as add on 
therapy to standard anti-hypertensive therapy in the reduction of blood pressure. 
 
 The study was conducted in the outpatient department of hypertensive 
clinic, department of internal medicine, madras medical college and government 
general hospital, Chennai. 
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 Out of 97 screened 60 patients who fulfilled the inclusion and exclusion 
criteria were recruited for the study. They were randomized into two groups, 
Group l, Group ll, each group consisting of 30 patients. Group l received 
amlodipine 5mg OD Group ll received amlodipine 5mg OD with Resveratrol 
100mg for a period of 4 weeks. 
 
 Efficacy variable such as systolic blood pressure and diastolic blood 
pressure were measured at the baseline, at the end of 2nd week at the end of 4th 
week of the study. Other hematological investigations such as complete 
hemogram, blood sugar, blood urea, serum creatinine, were done at the baseline, 
at the end of 2nd week at the end of 4th week of the study and analyzed for any 
statistical significance. There is no statistical significance among the study groups 
in demographic characteristics.  
 
 In this study resveratrol in the dose of 100mg added with amlodipine 
produces significant decrease in systolic blood pressure at the end of 1 month. 
 
 Resveratrol at the dose of 100 mg when added with amlodipine 5mg OD 
causes statistical significant reduction of systolic blood pressure of 11.15% at the 
end od 1st month of the study. Amlodipine 5mg OD alone group produces 
reduction of systolic blood pressure of 3.45% at the end of one month of the 
study. 
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 In this study,  resveratrol at the dose of 100 mg when added with 
amlodipine 5mg OD causes statistical significant reduction of diastolic blood 
pressure 12.72% at the end of one month of the study. Amlodipine 5mg OD alone 
group produces reduction of diastolic blood pressure of 7.08% at the end of one 
month of the study. 
 
 Other hematological and biochemical parameters were measured at the 
baseline, at the end of 2nd week, and at the end of 4th week found to have no 
statistical difference among the study groups. 
 
 Mild adverse effects such as nausea, vomiting, dyspepsia, diarrhea, 
dizziness, headache, cough and fatigue occurred among study groups which does 
not show any statistical significant difference ( P=0.69 ) among the groups and all 
the adverse effect subsided without any medications.  
 
 Hence,  resveratrol at the dose of 100mg / day along with amlodipine 5mg 
OD produces significant reduction of systolic and diastolic blood pressure to the 
desirable levels. 
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CONCLUSION 
 
From our study, we conclude that; 
 Resveratrol at the dose 100mg OD as an add on therapy to amlodipine 5mg 
OD causes significant reduction of both systolic and diastolic blood 
pressure. 
 Resveratrol OD supplementation to the standard anti-hyperactive drugs 
may produce better reduction of blood pressure levels. 
 Resveratrol may be recommended as an adjuvant to regular anti-
hypertensive regimen to reduce cardiovascular and cerebrovascular risks 
associated with hypertension.  
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APPENDIX – I 
 
ABBREVATIONS 
 
AA   :  Ascorbic acid 
ACE   : Angiotensin converting enzyme 
ADH   : Anti diuretic hormone 
ALT   : Aspartate aminotransferase 
ARBs   : Angiotensin receptor blockers 
ASD   : Autism spectrum disorder 
AST   : Aspartate aminotransferase 
BMI   : Body Mass Index 
BS   : Blood Sugar 
CD   : Collecting duct 
Cre   : Creatintine 
CRP   : C-reactive protein 
CVAs   : Cerebrovascular accidents 
CVD   : Cardiovascular disease 
DBP   : Diastolic blood pressure 
DCT   : Distal convoluted tubule 
dl   : Deciliter 
ELISA  : Enzyme linked immunosorbent assay 
Hb   : Hemoglobin 
HDL   : High density lipoprotein 
  
  
HT   : Hypertension 
ICAM-1  : Intercellular adhesion molecule 
IL-6   : Interleukin 6 
JAMA  : The Journal of the American  Medical Association 
Kg   : Kilogram 
LDL   : Low density lipoprotein 
MCP-1  : Monocyte chemoattractant protein 
Mg   : Milligram 
MI   : Myocardial infarction 
Mm Hg  : Millimeter of mercury 
MR   : Mineralocorticoid receptor 
RA   : Rheumatoid arthritis 
RESV              : Resveratrol 
RTI   : Respiratory tract infection 
SAP   : Serum alkaline phosphatase 
SBP   : Systolic blood pressure 
SGOT   : Serum glutamic oxaloacetic transaminase 
SGPT   : Serumglutamic pyruvic transaminase 
TNF-α  : Tumor necrosis factor α 
TPR   : Total peripheral resistance 
Vit   : Vitamin  
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